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Introduction 
Diabetic retinopathy (DR) is an important  complication of diabetes which progresses 
from mild to moderate nonproliferative change in retinal microvascular architecture 
and arterial blood flow to severe proliferative vascular abnormalities [1, 2]. It is widely 
recognized as the most frequent cause of visual impairment and legal blindness 
among adults aged 20-74 [3], especially in type 1 diabetic (T1DM) patients [4]. 
According to the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) 
nearly all T1DM patients develop retinopathy during the first two decades of the 
disease [5]. Hyperglycaemia has been proposed as a major risk factor of DR 
development and progression in The Diabetes Control and Complications Trial 
(DCCT) [6]. Numerous studies suggested that hyperglycaemia induces hemodynamic 
pathways leading to endothelial dysfunction which plays a crucial role in intimal 
denudation, DR induction and deterioration [7, 8]. Interestingly, there is also evidence 
that oscillating hyperglycaemia may cause more damage than persistent 
hyperglycaemia, probably due to increase in oxidative stress [9]. The retinal 
endothelium has a limited capacity of self-reparation since it is made of terminally 
differentiated cells with a low proliferative potential. That is why the reparation 
process is accomplished through the endothelial progenitor cells (EPCs) located in 
the bone marrow and mobilized into circulation mostly via the up regulation of the 
stromal derived factor α (SDFα) or its receptor [10]. The impairment in this process is 
demonstrated in experimental diabetes models [11]. SDFα is a pro-angiogenic 
peptide cleaved by enzymatic activity of dipeptidyl peptidase-4 (DPP4), a protease 
with elevated ubiquitously expression and activity in T1DM subjects [12, 13]. DPP4 
inhibitors are successfully implemented in treatment of type 2 diabetes mellitus 
(T2DM) as a group of oral hypoglycaemic agents preventing the degradation of 
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endogenous incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP) which seem to have an effect beyond 
glycaemic control [14]. There are several studies indicating that DPP4 inhibitors 
might have beneficial effect on nonproliferative retinopathy (NPR) development as 
well as on its progression to proliferative retinopathy (PR) [15- 17]. Thus, we aimed to 
explore the relationship between serum DPP4 activity and DR in T1DM patients. 
 
Materials and methods 
This cross-sectional study undertaken at the University Clinic for diabetes, 
endocrinology and metabolic diseases Vuk Vrhovac (Zagreb, Croatia) recruited 44 
T1DM C-peptide negative (C-peptide <0.5 ng/mL) patients aged >18 and <65 years 
comming for their comprehensive annual review. The sample size was in accordance 
with G power 3.1.7 calculation for correlations (two tailed t test, total sample size=44, 
α=0.05, 1-β=0.8, ρ=0.4). The inclusion criteria were: age at onset of diabetes 
younger than 40 years, positive autoantibodies and time to definite insulin therapy 
less then a year. Non inclusion criteria were: medical history of cardiovascular 
diseases or electrocardiogram (ECG) evidence of ischemic heart disease, any 
systemic disease and any infection in the previous month, thyroid hormone therapy, 
medications that might affect glucose metabolism and insulin sensitivity such as 
glucocorticoids or oral contraceptives. The study subjects could be using 
antihypertensive or lipid lowering drugs (i.e., statins: atorvastatin and simvastatin). 
The detailed description of the methods concerning anthropometric measurement 
and standard laboratory procedurs was conducted as previously described [19]. 
Fasting venous blood samples were collected for the determination of biochemistry 
panel, lipid profile status, glycated haemoglobin A1c (HbA1c) and serum DPP4 
activity. After clotting, the sera were separated and kept at −70°C until the 
determination of enzymatic activity. DPP4 activity was measured by a colorimetric 
assay procured from Sigma, St. Louis, MO, USA in a microplate reader (Cary Eclipse 
Varian, Agilent Technologies) at 460 nm, 37⁰C in a continuous monitoring for 35 
minutes. In this assay, DPP4 cleaves H-Gly-Pro-AMC to release a florecent product, 
7-Amino-4-Methyl  Coumarin (AMC) which can be measured spectrophotometrically.  
All the DPP4 assays were run in duplicates. Briefly, 50 μL of serum sample was 
added to 96-well plates, followed by the addition of 10 μL assay buffer. After 10 min 
of pre-incubation at 37⁰, the enzymatic reaction was started with the addition of 40 μL 
of Master Reaction Mix containing 2 μL substrate and 38 μL of the assay buffer. 
Liberation of AMC was monitored continuously at excitation 360 nm and emission 
460 nm every 5 min for up to 35 min in a 96-well black flat bottom plate. Fluorometric 
catalysis rates were determined from the linear portion of the curve of the increase in 
fluorescence and were calculated as the slope of the regression line determined from 
the line. DPP4 activity was expressed as pmole/min/mL (U/L). One unit of activity 
was defined as the amount of enzyme which will hydrolize the DPP4 substrate to 
yiled 1.0 µmole of AMC per minute at 37⁰C. 
Diabetic retinopathy was tested in specialized clinical ambulance by ophthalmologist- 
retinal specialist. Retinopathy was diagnosed by binocular indirect slit lamp 
fundoscopy and fundus photography after mydriasis with eye drops containing 0.5 % 
tropicamide and 5 % phenylephrine. Color fundus photographs of two fields (macular 
field, disc/nasal field; macular field: positioned in such a way that the exact center of 
the optic disc laid at the nasal end of the horizontal meridian of the field view; 
disc/nasal field: such that the optic disc was positioned one disc-diameter in from the 
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temporal edge of the field, on the horizontal meridian) of both eyes were taken with a 
suitable 45° fundus camera (VISUCAM, Zeiss) according to the EURODIAB retinal 
photography methodology [19]. EURODIAB classification scheme was used because 
it uses two-field 45° fundus photography and standard photographs to grade retinal 
lesions. In each patient the "worse" eye was graded for retinopathy using fundus 
photographs. Patients were classified in 2 groups: absence of DR and DR (both 
PR+NPR) presence since NPR may progress to PR and therefore, patients with DR 
may have possibly belong to the second group at a certain time point.  
Data analysis and Statistics 
The data distribution was assessed by Shapiro-Wilk test. All the continuous variables 
were log-transfrormed and reported as mean values and 95%CI of means, whereas 
categorical variables were reported as numbers and percentages. Because we found 
normal distribution of the data, the differences between three study groups were 
tested by one-way ANOVA followed by Bonferroni’s correction for multiple 
comparisons while. The differences between two study groups were tested by 
Student’s t-test while the categorical variables were analysed by the χ2 test. Binary 
logistic regression analysis was used to predict the probabilities of the associations of 
variables that reached significance in the univariate analysis with DR groups 
including the non-significant possible confounding factors (age and gender). Level of 
statistical significance was chosen to be 0.05. Statistical analysis was performed by 
Statistical Package for the Social Sciences (SPSS) ver. 17.0 and MedCalc 11.0 for 
Windows. 
Results 
The clinical characteristics and the fasting serum DPP4 activity of total 44 T1DM 
patients included in this cross-sectional study are detailed described in Table 1. 
Briefly, there were 28 (63.6%) male patients, mean age 45.36 years, diabetes 
duration 23.71 years, glycated haemoglobin A1c (HbA1c) of 7.4%. Thirty patients 
(68.2%) were using statins, i.e. atorvastatin and 22 (50%) antihypertensive agents. 
Twelve (27.3%) patients have had previous laser photocoagulation due to PR. They 
were stratified into two groups according to retinopathy prevalence. Group 1 
comprised 14 (31.85%) with DR absence and Group 2 30 (68.15%) patients with both 
NPR (N=21, 47.70%) and PR (N=9, 20.45%) prevalence. The group 1 had 
significantly shorter diabetes duration (16.43 vs 27.1 years, p=0.002), lower HbA1c 
level (6,9 vs 7,9 vs 7,7 %, p=0.019) as well as lower fasting serum DPP4 activity 
(25,85 vs 33,39 vs 34,91 U/L, p<0.001) when compared to second group (Table 
2.).History of previous laser photocoagulation was positive only in the second group 
(12 vs 0; p<0.00001). There were no patients with the history of laser 
photocoagulation due to macular oedema. The between group difference in the 
statins of antihypertensive therapy use did not reach statistical difference (data not 
shown). In the binary logistic regression model adjusted for age, gender, diabetes 
duration, HbA1c level and history of laser photocoagulation DPP4 activity remained 
associated with DR (1.637 (1.129-2.373); p=0.009)) (Table 3.). 
Discussion 
Since DPP-4 inhibitors have been successfully introduced in T2DM treatment 
showing beneficial pleiotropic effect beyond glycaemic control for this class of drugs 
[14, 20] and simultaneously growing body of evidence about increased serum DPP4 
activity in T1DM patients [12, 13], this cross-sectional study was designed primarily in 
order to elucidate the possible association of serum DPP4 activity and DR as most 
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frequent microvascular complication in diabetes [3, 4]. Metabolic and anthropometric 
variables and fasting serum DPP4 activity were assessed in two groups of T1DM 
patients according to the DR prevalence. Beyond already well-established factors 
associated with DR (diabetes duration and HbA1c), we showed that serum DPP4 
activity is significantly higher in T1DM patients with DR and that the association 
remained significant in the binary regression analysis after appropriate adjustments. 
To the best of our knowledge there is no data about DPP4 activity and DR in T1DM 
at the time. Although the effect of DPP4 inhibition on diabetic vasculature is still being 
discussed, their clinical application in T2DM glycaemia management is reported to 
provide beneficial effects regarding oxidation, apoptosis and vasoprotection, 
suggesting that it might be a useful tool in DR improvement [15-17].  
It is well established that EPCs are nowdays considered a mirror of cardiovascular 
health [21] and their circulating levels are decreased in diabetic subjects compared to 
healthy controls [10].Tissue ischemia is the strongest stimulus for EPCs mobilization 
from bone marrow [11]. Avogardo et al. (2011) [8] proposed that the majority of 
cytokines which mediate EPCs mobilization do so via modulation SDFα or its 
receptor, CXCR4. Moreover, in order to heal damaged endothelium, EPCs are 
required to migrate from bloodstream to target tissues which is again mediated by 
high local levels of SDFα. All those pathways are attenuated by inceased DPP4 
activity since it degradates SDFα. That is why they consider pharmacological 
inhibition of circulating DPP4 activity might restaurate hyperglycaemia induced 
endothelial dysfunction, i.e. mediate endothelial repairment. In theory, that could 
explain our finding regarding increased DPP4 activity and the DR prevalence, 
especially when concerning NPR. However, since NPR may progress to PR, the 
increased DPP4 activity association with a DR prevalence might seem paradoxically. 
It is expected that higher DPP4 activity leads to SDFα cleavage and the decreased 
neovascularization process which exists in PR. However, this DPP4 mediated 
retinopathy angiogenic paradox can currently be explained by two theories. First, 
there are evidence that peripheral EPCs from human T1DM patients with PR display 
higher clonogenic potential and enhaced endothelial differentiation [22, 23] so we 
may speculate that those EPCs overcome the process of endothelial reparation and 
lead to pathological endothelial proliferation. Second, hyperglycaemia induced retinal 
ischemia induces pericyte loss, an early event leading to endothelial activation and 
the release of local pro angiogenic factors resulting in endothelial proliferation and 
PR development [8, 25]. In addition, DPP4 inhibition reduces microvascular tone 
through direct nitric oxide (NO) system preventing acute retinal ischemia events [26]. 
Therefore, we can generate the conclusion that increased serum DPP4 activity might 
increase vascular tonus resulting in pericyte loss and retinal endothelial proliferation. 
Finally, but not less important to emphasise once again, hyperglycaemia expressed 
as HbA1c is recognized as the most important factor for DR development and 
progression in T1DM [6]. Increased systemic DPP4 activity degradates incretine 
hormones GLP-1 and GIP which analogues are primarily used in T2DM [24] 
glucoregulation, but might also benefit glycaemic control in patients with T1DM as 
recently suggested [27]. The use of GLP-1 analogues provides blood lipid 
improvements, lowers blood pressure and improves markers of renal function, in 
particularly, albuminuria which are all shown to be associated with DR [6, 7], in 
addition it has been observed the more homogenecity with human GLP-1 the 
observed effect seem to provide a better effect  [14, 24, 28, 29]. The increased serum 
DPP4 activity might increase the degradation process of endogenous GLP-1 
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resulting in worsening of the mentioned parameters which has also been observed in 
our study results although the difference did not reach statistical difference.  
This study has several limitations that should be pointed out: the sample size was too 
small and we accessed only systemic DPP4 activity, did not measure EPCs nor GLP-
1 so any general conclusion about its relationship with DR cannot be made. Despite, 
we can conclude that serum DPP4 activity may be associated with both DR types in 
T1DM patients independently of HbA1c and diabetes duration or that it might play an 
important role in pathophysiology of its development. However, further study 
investigation in a larger sample are warranted to elucidate the question whether there 
is a strong association between DPP4 activity and DR severity and/or progression 
and if so, what is the exact underlying mechanism. 
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Tables 
Table 1. Clinical characteristics and the fasting serum DPP-4 activities of type 1 
diabetic patients with mean values indicated in bold letters and (95% Confidence 
Intervals of means indicated in parenthesis) or absolute numbers in bold letters (and 
percentages in parenthesis) 
Age (years) 45,36 (41,47 - 49,26) 
Gender (male, N (%)) 28               (63.6%) 
Diabetes duration (years) 23,71 (20,42 - 26,99) 
HbA1c (%) 7,4 (7,1 - 7,7) 
BMI (kg/m
2
) 25,93 (24,98 - 26,88) 
Systolic blood pressure (mmHg) 128,97 (124,09 - 133,86) 
Dyastolic blood pressure (mmHg) 80,91 (78,59 - 83,24) 
Total cholesterol (mmol/L) 4,9 (4,7 - 5,2) 
HDL cholesterol (mmol/L) 1,59 (1,51 - 1,69) 
LDL cholesterol (mmol/L) 2,85 (2,61 - 3,09) 
TG (mmol/L) 1,09 (0,97 - 1,23) 
VLDL cholesterol (mmol/L) 0,51 (0,45 - 0,56) 
DPP4 activity (U/L) 31,42 (29,68 - 33,15) 
Urine albumine excretion (mg/24h) 12,41 (8,022 – 19,18) 
CKD-EPI (mL min
-1
 1.73m
-2
) 100,71 (94,27-107,13) 
Nonproliferative retinopathy (%) 21 (47.7 %) 
Proliferative retinopathy (%) 9 (20.45 %) 
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Table 2. Clinical and laboratory characteristics according to the diabetic retinopathy 
prevalence among groups of type 1 diabetic patients with mean values indicated in 
bold letters and (95% Confidence Intervals of means indicated in parenthesis) or 
absolute numbers in bold letters (and percentages in parenthesis) 
  Without retinopathy 
(N=14) 
With retinopathy (N=30) 
Mean 95% CI Mean 95% CI 
Age (years) 44,64 37,24 - 52,05     45,7  40,84 -
 50,56 
Gender (male, N (%) 11 
(78,57%) 
 17 (56,67%)  
Diabetes duration 
(years)* 
16,43 12,44 - 20,42     27,1  23,09 -
 31,12  
HbA1c (%)* 6,9 6,4 - 7,4     7,7  7,19 -
 8,16 
BMI (kg/m2) 26,43 24,62 - 28,24     25,7  24,52 -
 26,87 
Systolic blood 
pressure (mmHg) 
125,94 117,65 -
134,81 
    130  123,92 -
136,09 
Dyastolic blood 
pressure (mmHg) 
78,69 75,16 - 82,39    76.7  70,31 - 
83,09 
Resting hearth rate 
(beats per minute) 
71,79 62,92 - 80,66 78,38 69,93 -
 86,84 
Total cholesterol 
(mmol/L) 
4,97 4,54 - 5,42    4,94  4,64 -
 5,25 
HDL cholesterol 
(mmol/L) 
1,52 1,41 - 1,63    1,63  1,51 -
 1,75 
LDL cholesterol 
(mmol/L) 
2,96 2,53 - 3,34    2,80  2,48 -
 3,11 
TG (mmol/L) 1,04 0,89 - 1,23 1,21  1,02 - 
1,41 
VLDL cholesterol 
(mmol/L) 
0,47 0,41 - 0,56    0,56  0,47 -
 0,65 
DPP4 activity (U/L)*+ 25,85 23,45  28,46   33,84  32,24 -
35,45 
Urine albumine 
excretion (mg/24h) 
8,71 3,73 - 20,29  14,54  8,56 -
 24,70 
CKD-EPI (mL min-1 
1.73m-2) 
102,57 91,54 -
 113,61 
99,83  91,51 -
 108,16 
Legend: *p<0.05; +standard deviation of the DPP4 activity for the group without DR is 
±4.83 and for the group with DR is ±4.31 U/L. 
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Table 3. Logistic regression analysis of  DPP4 activity with presence of DR. Data are 
OR (95% CI) from separate models.  
Independent                        Model A                  Model B                        Model C                      Model D 
 variable        
DPP4 activity 
 (U/L)                         1.384(1.151- 1.664)*    1,403(1.154-1.705)*    1,391(1.139-1.698)*    1.887 (1.073-3.321)*  
                                         MODEL E 
                                 1.637 (1.129-2.737)
 
*p < 0.05. 
Legend: Model A-crude model; Model B-crude model adjusted bx age and gender; Model C-crude model adjusted 
by age, gender and disease duration; Model D-crude model adjusted by age, gender, disease duration and 
HbA1c level; MODEL E- crude model adjusted by age, gender, disease duration, HbA1c level and previous laser 
photocoagulation surgery. 
 
